- Home
- TBI vs MXCT Comparison
TBI vs MXCT Comparison
Compare TBI & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBI
- MXCT
- Stock Information
- Founded
- TBI 1985
- MXCT 1999
- Country
- TBI United States
- MXCT United States
- Employees
- TBI N/A
- MXCT N/A
- Industry
- TBI Professional Services
- MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- TBI Consumer Discretionary
- MXCT Health Care
- Exchange
- TBI Nasdaq
- MXCT Nasdaq
- Market Cap
- TBI 204.9M
- MXCT 239.2M
- IPO Year
- TBI 1996
- MXCT 2021
- Fundamental
- Price
- TBI $6.21
- MXCT $2.24
- Analyst Decision
- TBI Buy
- MXCT Strong Buy
- Analyst Count
- TBI 1
- MXCT 1
- Target Price
- TBI $10.00
- MXCT $9.00
- AVG Volume (30 Days)
- TBI 197.4K
- MXCT 717.0K
- Earning Date
- TBI 08-04-2025
- MXCT 08-06-2025
- Dividend Yield
- TBI N/A
- MXCT N/A
- EPS Growth
- TBI N/A
- MXCT N/A
- EPS
- TBI N/A
- MXCT N/A
- Revenue
- TBI $1,534,794,000.00
- MXCT $37,675,000.00
- Revenue This Year
- TBI $0.80
- MXCT $8.82
- Revenue Next Year
- TBI $6.90
- MXCT $21.12
- P/E Ratio
- TBI N/A
- MXCT N/A
- Revenue Growth
- TBI N/A
- MXCT N/A
- 52 Week Low
- TBI $3.45
- MXCT $2.00
- 52 Week High
- TBI $12.29
- MXCT $5.20
- Technical
- Relative Strength Index (RSI)
- TBI 45.22
- MXCT 48.76
- Support Level
- TBI $6.36
- MXCT $2.16
- Resistance Level
- TBI $6.89
- MXCT $2.29
- Average True Range (ATR)
- TBI 0.27
- MXCT 0.12
- MACD
- TBI -0.09
- MXCT 0.01
- Stochastic Oscillator
- TBI 13.78
- MXCT 71.20
About TBI TrueBlue Inc.
TrueBlue Inc is a provider of staffing and workforce management solutions. Its reportable segments include PeopleReady offers industrial staffing services. PeopleManagement offers contingent and productivity-based on-site industrial staffing services and PeopleScout offers recruitment process outsourcing, talent advisory services, and managed service provider services. It generates maximum revenue from the PeopleReady segment.
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.